Explore All 789 Divestiture Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | December 26, 2023 |
| Target | Atreca - Antibody s Related Assets and Materials |
| Sector | Life Science |
| Buyer(s) | Immunome |
| Sellers(s) | Atreca |
| Deal Type | Divestiture |
| Deal Value | 6M USD |
FILTER BY
| Category | Company |
|---|---|
| Founded | 2006 |
| Sector | Life Science |
| Employees | 131 |
| Revenue | 9M USD (2024) |
Immunome is a biopharmaceutical company utilizing its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome’s proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. Immunome was founded in 2006 and is based in Bothell, Washington.
| Deal Context for Buyer | # |
|---|---|
| Overall | 2 of 3 |
| Sector: Life Science | 2 of 3 |
| Type: Divestiture | 1 of 2 |
| Country: United States | 2 of 3 |
| Year: 2023 | 2 of 2 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-06-29 |
MorphImmune
West Lafayette, Indiana, United States Morphimmune is a biotechnology company focused on developing targeted oncology therapeutics. The company’s proprietary Targeted Effector platform selectively delivers payloads to diseased cells. The targeted approach reduces toxicity and increases the efficacy of known effector molecules, ultimately improving outcomes for patients. Morphimmune is based in West Lafayette, Indiana. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-02-06 |
Ayala Pharmaceuticals - AL102
Rehovot, Pennsylvania, United States Ayala Pharmaceuticals' AL102 is an investigational small molecule gamma-secretase inhibitor currently being evaluated in the randomized Phase 3 RINGSIDE international trial for the treatment of desmoid tumors – a debilitating soft tissue malignancy. Ayala Pharmaceuticals' AL102 is based in Rehovot, Pennsylvania. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 2010 |
| Sector | Life Science |
| Employees | 134 |
Atreca is a biotechnology company developing novel oncology therapeutics based on a deep understanding of the human immune response. Atreca was founded in 2010 and is headquartered in South San Francisco, California.
| Deal Context for Seller | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science | 1 of 1 |
| Type: Divestiture | 1 of 1 |
| Country: United States | 1 of 1 |
| Year: 2023 | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
